MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
Solid Biosciences Operating Income 2011-2026 | SLDB
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Solid Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -179 M | -130 M | -104 M | -106 M | -72.3 M | -88.4 M | -119 M | -75.7 M | -54.9 M | -25.6 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -25.6 M | -179 M | -95.6 M |
Quarterly Operating Income Solid Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -48.1 M | -41.7 M | -40.1 M | - | -35.2 M | -27.8 M | -26.9 M | - | -23.1 M | -26.8 M | -32 M | - | -21.1 M | -25.4 M | -25.4 M | - | -18 M | -18.7 M | -16.9 M | - | -21.2 M | -19 M | -26.9 M | -32.3 M | -29.7 M | -27 M | -30.3 M | -22.4 M | -19.2 M | -18.2 M | -16 M | -15.2 M | -13.7 M | -11.9 M | -14.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -11.9 M | -48.1 M | -24.8 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
China Pharma Holdings
CPHI
|
-4.59 M | $ 0.57 | -9.62 % | $ 9.95 M |  China |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.32 | 0.3 % | $ 86.3 M |  Canada |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.01 | -0.5 % | $ 410 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.13 | 2.62 % | $ 44 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 4.99 | -2.25 % | $ 1.82 B | Canada |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 23.2 | 2.43 % | $ 1.07 B | USA |
 |
Harrow Health
HROW
|
30.5 M | $ 35.2 | 3.53 % | $ 1.29 B | USA |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Perrigo Company plc
PRGO
|
-1.12 B | $ 9.64 | 0.73 % | $ 1.34 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.43 | -5.34 % | $ 286 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.37 | 0.74 % | $ 3.37 M | Canada |
 |
Rockwell Medical
RMTI
|
-6.67 M | $ 1.03 | 0.98 % | $ 24 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.1 | 4.1 % | $ 241 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.34 | -1.47 % | $ 402 M | Canada |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.9 | 2.8 % | $ 44.9 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.34 | -8.24 % | $ 2.9 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.41 | -2.43 % | $ 317 M | USA |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 0.96 | -0.87 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.66 | 3.26 % | $ 4.12 B | Canada |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 16.51 | 17.93 % | $ 106 M | USA |
 |
TherapeuticsMD
TXMD
|
-8.52 M | $ 2.29 | -0.87 % | $ 23.9 M | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.29 | -0.43 % | $ 309 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.36 | 0.53 % | $ 16 B | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.77 | 1.06 % | $ 3.32 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |